High APOBEC3B expression has been associated with poor response to Raf inhibitors in glioma, and certain APOBEC3-induced mutations may predict resistance to Raf inhibitors and EGFR inhibitors in multiple myeloma and lung cancer, respectively [82, 158]. Here, EGFR is linked to lung cancer.